Tag: GlobeNewswire

Maiden Drilling Validates Stacked Helium Potential and Discovery Model

New REV Video: Why Helium Matters
https://youtu.be/V8IOCW8YyBo

VANCOUVER, British Columbia, Oct. 30, 2026 (GLOBE NEWSWIRE) — REV Exploration Corp. (“REV” or the “Company”) (TSXV: REVX; OTCID: REVFF) is pleased to announce that highly elevated Helium concentrations with exceptional reservoir properties via geophysical logs have been identified across multiple distinct geological horizons in its maiden drilling program at the Aden Dome Property along the Alberta-Montana border, setting up the near-term potential of a new Helium discovery in the Sweet Grass Corridor as the Company also prepares for first-ever drilling at its nearby West Butte Project.

Highlights

• Detailed evaluation of the several Helium zones encountered begins the week of November 2, 2026, as REV has immediately contracted a service rig to test for pressure, reservoir quality, gas composition and potential deliverability;
• The discovery of Helium across multiple horizons provides compelling evidence for an active Helium charge, migration pathway from source and trapping mechanism at the Aden Dome, while materially expanding the number of potential reservoir targets for future drilling and completion operations;
• While drilling for Helium, REV encountered a strong Natural Hydrogen show in the basement complex near the contact with the Basal Cambrian Sandstone Formation;
• Initial success at Aden will help to optimize drill targets for the Company’s promising West Butte Project 20 miles to the west-southwest and several additional play concepts are being developed in tandem on additional properties;
• The Trump administration, through the U.S. Department of Energy, recently added Helium to America’s Critical Material List.

Mr. Shayne Neigum, VP-Exploration for REV, commented: “The identification of Helium in multiple independent horizons is particularly significant because it suggests Helium charge has migrated from the source rocks through the geological system and accumulated at multiple stratigraphic and structural levels. Equally important, these results do not exist in isolation. They complement the significant exploration success already achieved nearby and provide further evidence that we are operating within a highly prospective Helium-rich regional system that we will test again shortly with our biggest project in Montana, West Butte.”

U.S. Department of Energy (DOE) Critical Material List Notice

On October 23, 2026, the U.S. Department of Energy announced that Secretary of Energy Chris Wright had designated Helium as a Critical Material due to its essential role in domestic manufacturing and high vulnerability to supply chain disruptions. The DOE highlighted Helium as non-substitutable for critical energy and technology functions, including semiconductor manufacturing, leak detection, and quantum computing. The designation reinforces the strategic importance of REV’s Helium portfolio in the Northern Great Plains.

Figure 1: Aden Dome Helium Project

Figure 2: Aden Dome Drilling with Montana’s Sweet Grass Hills in Background

CEO Commentary

Mr. Jordan Potts, REV CEO and Director, stated: “Helium is essential to America’s economic and national security and its technological future. These exciting initial results at Aden are an important step as we build an American-leading, target-rich Helium portfolio.”

About REV Exploration Corp.

REV is a mineral exploration company with a diversified portfolio of strategic mining assets, together with meaningful and growing exposure to the Helium and Natural Hydrogen sectors focused on America’s Northern Great Plains and southernmost Alberta along the Montana border. The Company owns oil and gas leasehold interests in Montana covering approximately 10,600 acres, in addition to a series of PNG leases in Alberta along the Alberta–Montana border, including the Aden Dome Project. REV also owns 6 million shares of MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF) and 12.4 million shares of Major Gold Corp., a private company that is pursuing a listing on the TSX Venture Exchange.

For further information on the Company, readers are referred to the Company’s website at REVexploration.com and its Canadian regulatory filings on SEDAR+ at sedarplus.ca.

REV Exploration Corp.
Unit 220 – 1060 Manhattan Dr.
Kelowna, BC V1Y 9X9
Tel: 604-682-7970
info@revexploration.com
REVexploration.com

Jordan Potts, CEO and Director

For further information, please contact:

Chad Levesque
Investor Relations
1-306-981-4753
info@revexploration.com

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking information”). Forward-looking information in this release includes statements regarding the scope, timing and results of the Aden Dome evaluation and testing program, expected to begin the week of November 2, 2026; assessment of pressure, reservoir quality, gas composition and potential deliverability; future drilling and completion operations; Helium and Natural Hydrogen potential and the regional exploration model; the use of Aden results to refine West Butte targets and the timing and results of drilling there; the Company’s ambition to build an American-leading, target-rich Helium portfolio; and the proposed listing of Major Gold Corp. on the TSX Venture Exchange.

Forward-looking information is based on management’s expectations and reasonable assumptions as of the date of this news release, including timely mobilization and availability of the contracted service rig, other equipment, technical personnel and service providers; site access, operating and weather conditions; the accuracy and reliability of geological information, sampling and testing; the Company’s ability to obtain required permits and financing on reasonable terms if required; satisfaction of applicable requirements for Major Gold Corp.’s proposed listing; and general economic, market and business conditions.

Forward-looking information involves risks and uncertainties that may cause actual results to differ materially from those anticipated, including the risk that testing may not confirm preliminary gas indications or establish concentrations, sustained flow rates, reservoir quality or deliverability sufficient to support commercial development; geological interpretations and the regional exploration model may not be confirmed; results at Aden or nearby properties may not be replicated at West Butte or other targets; operations may encounter mechanical failure, hole instability, cost overruns, delays or accidents; required permits or financing may not be obtained; and Major Gold Corp.’s proposed listing may be delayed or not completed. Other risks include land tenure, environmental compliance and community relations; commodity prices and currency fluctuations; access to capital and dilution; reliance on key personnel and third-party contractors; and general economic, market and political uncertainties.

The reported Helium and Natural Hydrogen indications do not, by themselves, establish commercially recoverable quantities or economic viability. Further testing and technical and economic evaluation are required. Investors should review the risk factors and other disclosure in the Company’s public filings on SEDAR+.

There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this news release, and the Company does not undertake any obligation to update or revise such information except as required by applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/fa97a691-4f65-49cf-bea2-9e90743ccb95
https://www.globenewswire.com/NewsRoom/AttachmentNg/bf5b0b31-0473-4cb3-b28d-2a36581d6de3

Parties agree in principle to pursue acquisition of 100% of Tranglo, subject to definitive documentation and agreement with Ripple Markets APAC

SINGAPORE, Oct. 30, 2026 (GLOBE NEWSWIRE) — Currenc Group Inc. (Nasdaq: CURR) (“Currenc” or the “Company”), a provider of artificial intelligence (AI) solutions to financial institutions, today announced that its wholly owned subsidiary, Seamless Group Inc. (“Seamless”), and New Margin Holding Limited (“New Margin”) have signed a reinstatement and amendment letter dated October 29, 2026 (the “Reinstatement Letter”) in relation to the share purchase agreement dated January 1, 2026 (the “SPA”) concerning Tranglo Sdn. Bhd. (“Tranglo”). The Reinstatement Letter reinstates the SPA effective from New Margin’s countersignature on October 29, 2026 and extends the longstop date to March 31, 2027. The parties have also agreed in principle to pursue a proposed acquisition of 100% of Tranglo’s issued share capital for aggregate consideration of US$666,666,666.67, subject to definitive documentation and the required cooperation and agreement of Ripple Markets APAC Pte. Ltd. (“RMA”).

Tranglo is a cross-border payment hub that facilitates international transactions for businesses and financial institutions, including remittances, business payments and mobile top-ups, through a network of banks, e-wallets and payout partners.

The reinstatement and proposed enlarged transaction represent an important step in Currenc’s previously announced plan to monetize its existing operating businesses and streamline its corporate structure. If completed, the proposed full acquisition would enable Currenc to monetize its entire interest in Tranglo. Subject to completion and the applicable settlement and payment arrangements, the Company intends to use net proceeds received from the sale of its Tranglo shares to repay indebtedness, fund working capital and support its AI and Web3 initiatives.

“We are pleased to have reinstated the SPA and established with New Margin a pathway toward a potential acquisition of 100% of Tranglo,” said Alex Kong, Founder, Executive Chairman and Chief Executive Officer of Currenc Group. “The extended timetable provides a framework to advance the remaining requirements. Completing the proposed transaction would be an important step in our strategy to monetize Tranglo, strengthen our balance sheet and focus resources on AI and Web3. We are focused on progressing the conditions and third-party arrangements required for closing.”

Ye Tian of New Margin commented, “We are pleased to have reinstated the SPA and agreed with Seamless to pursue a potential acquisition of 100% of Tranglo. Tranglo has built a valuable cross-border payments platform with an extensive international network, and we see significant potential in its next phase of growth. We are committed to working closely with Seamless to advance the remaining regulatory, licensing and documentation requirements and to pursue the third-party arrangements necessary to support completion.”

Transaction Overview

As previously announced on January 2, 2026, the original SPA provided for New Margin to acquire 100,465 ordinary shares of Tranglo, representing 60% of its issued share capital, for US$400 million, with US$200 million payable at closing and US$200 million payable within 90 days after closing. The SPA terminated automatically when the closing conditions were not satisfied or waived by September 30, 2026. The reinstated SPA retains the same aggregate purchase price and payment structure and, except for the express amendments in the Reinstatement Letter, all other terms and conditions remain unchanged and in full force and effect upon reinstatement.

RMA previously exercised tag-along rights in respect of all 66,977 ordinary shares held by it in Tranglo. As disclosed in the Company’s Annual Report on Form 20-F, under the existing transaction framework Seamless would sell approximately 60,279 Tranglo shares, representing approximately 36% of Tranglo’s issued share capital, for gross consideration of approximately US$240 million, and RMA would sell the balance of the 100,465 shares, representing approximately 24% of Tranglo, such that New Margin would acquire a total of 60% on the same terms. These amounts are before deduction of any amounts applied to Seamless’s judgment debt as described below.

Under the proposed enlarged transaction, New Margin would acquire 100% of Tranglo for aggregate consideration of US$666,666,666.67, calculated on a pro rata basis to the purchase price under the SPA. Approximately US$400 million would be attributable to Seamless’s entire 60% interest, and approximately US$266.7 million would be attributable to RMA’s 40% interest and would be payable to RMA rather than to Seamless or the Company. If the proposed full acquisition is completed, Seamless’s gross consideration would therefore increase from approximately US$240 million under the existing tag-along framework to approximately US$400 million for its entire interest, before applicable settlement and payment deductions.

RMA is not a party to the Reinstatement Letter. The proposed acquisition of RMA’s shares, settlement of Seamless’s judgment debt, discharge of the charging order and any agreed standstill are intended to be documented through a separate tripartite agreement among Seamless, New Margin and RMA (the “Tripartite Agreement”). Beyond any obligation already existing under the SPA and the Shareholders’ Agreement, New Margin has no obligation to acquire or make any payment for RMA’s shares unless and until the Tripartite Agreement is executed. The proposed 100% acquisition therefore remains subject to definitive documentation and the cooperation and agreement of RMA, where required.

Path to Completion

Seamless and New Margin have agreed to cooperate fully and in good faith and use reasonable endeavours to progress the outstanding conditions. Their immediate priorities include renewal of Tranglo’s money services business licence, required regulatory change-of-control and director approvals, execution of the Deed of Ratification and Accession, New Margin’s funding arrangements and matters relating to discharge of the charging order over the shares owned by Seamless. The indicative timetable targets execution of the Tripartite Agreement by December 31, 2026 and satisfaction or waiver of the remaining conditions and closing by the extended longstop date.

As disclosed in the Company’s Report on Form 6-K dated October 7, 2026, the High Court of Malaya made absolute a charging order over the 100,465 Tranglo shares owned by Seamless in connection with an unsatisfied Singapore judgment for a principal sum of US$23,952,480.00, plus late payment charges and certain costs. Under the Reinstatement Letter, any payment to RMA in satisfaction of Seamless’s judgment debt would be made from the first US$200 million tranche otherwise payable to Seamless and separately identified from consideration payable for RMA’s own shares. The parties will seek RMA’s agreement to a standstill pending closing and to discharge the relevant security and discontinue related enforcement proceedings upon performance of the agreed settlement obligations. No standstill has been agreed as of the date of this press release, and RMA is entitled to commence further enforcement proceedings and seek a sale of the charged shares.

Founded in 1999, NewMargin Ventures (“NewMargin”) is a private equity firm that, according to information provided by NewMargin, manages over RMB40 billion in assets and has invested in more than 300 companies, with approximately 100 portfolio companies having completed IPOs or strategic exits. NewMargin intends to complete the transaction through its affiliated offshore investment entity, New Margin Holding Limited.

Completion of the transaction contemplated by the reinstated SPA remains subject to satisfaction or waiver of the applicable conditions, including required regulatory approvals and third-party consents, in accordance with the SPA’s terms. Completion of the proposed 100% acquisition is additionally subject to execution and implementation of the Tripartite Agreement and any other required definitive documentation. There can be no assurance that either transaction will be completed on the terms or timetable described in this press release, or at all. No advance purchase-price payments have been made as of the date of this press release.

Tranglo accounted for a majority of the Company’s revenue for the year ended December 31, 2025, and completion of the sale of the Company’s entire interest would result in the disposition of its principal operating business. The Company’s Annual Report on Form 20-F includes disclosure regarding substantial doubt about the Company’s ability to continue as a going concern.

About Currenc Group Inc.

Currenc Group Inc. (Nasdaq: CURR) is a fintech company that provides artificial intelligence (AI) solutions to financial institutions. The Company’s AI solutions, including Seamless AI Call Centre and other AI-powered agents, are designed to reduce costs, increase efficiency and improve customer satisfaction for banks, insurance companies, telecommunications companies, government agencies and other financial institutions. Through Tranglo, the Company’s digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 global payment services. In April 2026, Currenc tokenized its ordinary shares on the Ethereum and Solana blockchains.

For additional information, please refer to www.currencgroup.com, the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 30, 2026, and its subsequent Reports on Form 6-K.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release—including statements regarding the satisfaction or waiver of closing conditions, licence renewal and regulatory and director approvals, New Margin’s funding arrangements, the Tripartite Agreement, any judgment settlement, standstill, discharge or enforcement of the charging order, the structure, timing, completion and potential benefits of the transaction and proposed 100% acquisition, estimated proceeds and their expected use, the Company’s ability to continue as a going concern, and its business strategy, plans and objectives—are forward-looking statements.

Many factors could cause actual results to differ materially from those described in these forward-looking statements, including: the SPA’s prior automatic termination and the possibility that conditions may again not be satisfied or waived by the extended longstop date; renewal of Tranglo’s money services business licence and receipt of required regulatory approvals; New Margin’s ability to demonstrate and provide the required funding; RMA’s willingness to execute the Tripartite Agreement and agree to a standstill and settlement; enforcement of the charging order, including a potential sale below the SPA purchase price; increases in the judgment debt and the resulting reduction in proceeds payable to Seamless; termination in specified circumstances; possible changes to the terms, structure or timing of the transaction; the Company’s liquidity and going-concern position if the transaction is not completed; and the risks described in the Company’s SEC filings, including its Annual Report on Form 20-F filed on April 30, 2026 and its Reports on Form 6-K furnished since that date.

Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law. All information provided in this press release is as of the date of this press release.

Investor & Media Contact

Currenc Group Investor Relations
Email: investors@currencgroup.com

Source: Currenc Group Inc.

MIAMI, FL, Oct. 30, 2026 (GLOBE NEWSWIRE) — Core AI Holdings, Inc. (Nasdaq: CHAI) (“Core AI” or the “Company”), a global AI technology and infrastructure company, today announced that Haggai Ravid has been appointed to its Board of Directors, effective immediately, following a unanimous vote of the Board approving his nomination.

Mr. Ravid brings more than 20 years of senior executive, investment banking and corporate finance experience, with a demonstrated track record of leading public companies, executing complex financial restructurings, raising capital, and driving strategic growth initiatives. His appointment further strengthens the Company’s Board with significant expertise in public company management, financial strategy, capital markets and mergers and acquisitions.

Most recently, Mr. Ravid served as Chief Executive Officer of Nasdaq traded Sadot Group Inc. from June 2025 through August 2026, where he led a comprehensive corporate turnaround, including a balance sheet restructuring, converting more than $5 million of merchant cash advances and other liabilities into equity, raising approximately $10 million through multiple financing tranches, and securing a $100 million equity line of credit. He also implemented significant cost-reduction initiatives, streamlined operations, and transformed the Company’s supply-chain business into an AI-driven platform. Since August 2026, Mr. Ravid has continued serving Sadot Group as an Executive Director, supporting its Board, strategic initiatives, capital markets activities and leadership transition.

Prior to Sadot Group, Mr. Ravid served as Chief Financial Officer of Nasdaq traded Seamless Group Inc. from December 2022 to December 2024, where he oversaw financial planning and budgeting, public company reporting and SEC compliance, and supported the Company’s de-SPAC process and capital markets activities.

Mr. Ravid also served as Chief Executive Officer of Cukierman & Company Investment House Ltd. from 2006 through 2022, where he led multiple business divisions spanning technology, fintech, mobility, healthcare, energy and other sectors. During his tenure, he directed complex strategic initiatives, cross-border mergers and acquisitions, and financial transactions totaling approximately $5 billion. Between 2015 and 2018, he additionally served as CEO of Cukierman & Company’s China operations, based in Shanghai, overseeing cross-border investment banking activities, capital raising and strategic relationships with Chinese regulatory and business organizations.

Earlier in his career, Mr. Ravid held investment banking and financial leadership positions in the United States and Israel, including at Twin Triangle Financial, MBI and Bank Leumi. His experience encompasses equity financing, SPAC transactions, equity lines of credit, venture lending, international underwriting, financial restructuring and strategic corporate development.

Mr. Ravid holds an MBA from Rutgers University and an undergraduate degree from Hebrew University.

Aitan Zacharin, Chief Executive Officer of Core AI, commented:

“We are very pleased to welcome Haggai to the Board of Directors. Haggai brings an exceptional combination of public company leadership, financial expertise, capital markets experience and strategic execution. His experience leading public issuers, securing financing and executing complex transactions will be particularly valuable as Core AI continues to execute on its long-term growth strategy.

As we build Core AI into a leading global AI technology and infrastructure company, having directors who understand the demands of the public markets and have a proven ability to create shareholder value is extremely important. Haggai’s depth of experience and strategic perspective will be a tremendous addition to our Board, and we look forward to working with him.”

Haggai Ravid, newly appointed Board Member of Core AI, commented:

“I am excited to join the Board of Core AI at such an important stage in the Company’s development. Artificial intelligence and the infrastructure required to support its continued expansion represent significant long-term opportunities. Core AI has an ambitious vision, and I believe the Company has an opportunity to build meaningful value through its strategic initiatives across the AI ecosystem.

I look forward to working with Aitan and the rest of the Board to support the Company’s strategic direction, strengthen its financial and corporate infrastructure, evaluate growth opportunities and help position Core AI for sustainable long-term growth and shareholder value creation.”

About Core AI Holdings, Inc.

Core AI Holdings, Inc. (NASDAQ: CHAI) is a global AI technology and infrastructure company focused on identifying, developing, and scaling AI-driven businesses that leverage next-generation technologies to address large, high-growth market opportunities. Core AI’s mission is to harness artificial intelligence to create transformative, scalable solutions across multiple verticals and drive long-term shareholder value.

Core AI Investor Relations

ir@coregaming.co

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Core AI’s current expectations and assumptions and are subject to risks, uncertainties, and changes in circumstances that may cause actual results to differ materially, as well as other risks described under “Risk Factors” in Core AI’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on May 15, 2026, and in subsequent SEC filings. Except as required by law, Core AI undertakes no obligation to update these forward-looking statements.

– Agreement complements revenue from standard gene expression and DRP® services

– Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the United States

– Strategy expands commercial use of existing laboratory capabilities

– Stenoparib remains the Company’s top development priority

TARPON SPRINGS, Fla., October 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—
today announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy.

CLIA certification is a U.S. regulatory requirement for laboratories performing testing on specimens from humans, such as blood, body fluids, and tissue. The agreement represents the first commercial validation of Allarity’s CLIA-certified laboratory services strategy following the Company’s receipt of CLIA certification in July 2026.

Under the agreement, Allarity will provide a European biotechnology company with development, validation and related laboratory services to support implementation of a proprietary precision oncology predictive device for use in the United States. Successful completion of the program could lead to ongoing commercial testing and CLIA-related service revenues.

“This agreement moves our newly established CLIA laboratory services strategy into commercial execution, building on our existing gene expression and DRP® services business,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “For shareholders, the opportunity is to generate additional value from capabilities we have already built while maintaining stenoparib as our top development priority.”

Allarity obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA) for its Hørsholm laboratory, in part to enable the Company to perform biomarker testing internally in support of the continued clinical development of stenoparib and its DRP® companion diagnostic strategy.

The Company also identified the opportunity to offer its CLIA-certified laboratory capabilities to other biotechnology and pharmaceutical companies, particularly European drug developers seeking laboratory support for precision oncology programs intended for U.S. clinical development or commercialization. This first commercial agreement provides an initial foundation for pursuing that broader service opportunity.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.

Allarity has completed its first Phase 2 trial evaluating stenoparib in patients with advanced ovarian cancer. The trial demonstrated promising and durable clinical benefit in patients with ovarian cancer who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from the trial were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature.

Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol focused on patients with platinum-resistant ovarian cancer, which began enrolling patients in the summer of 2025. The amended protocol enrolls only platinum-resistant or platinum-ineligible patients and is designed to advance the clinical development of stenoparib toward potential FDA approval.

In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment, and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

The DRP methodology is based on the comparisons of sensitive and resistant human cancer cell lines, and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.

The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the successful performance of services under the Company’s CLIA-certified laboratory services agreement; the potential for the agreement and the Company’s laboratory capabilities to generate recurring commercial revenue; future demand for the Company’s CLIA-certified services; the continued development of stenoparib and the Company’s DRP® companion diagnostic strategy; and the Company’s expectation that its existing working capital will be sufficient to fund operations into the summer of 2028. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks that the development or validation activities may not be successfully completed; that the customer’s program may not advance to commercial testing; that the agreement may not generate recurring revenues or lead to additional commercial agreements; changes in applicable regulatory requirements; and the possibility that the Company’s operating expenses, financing needs or other circumstances may differ from current expectations. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

###

Company Contact:
      investorrelations@allarity.com
        
Media Contact:
     Thomas Pedersen
     Carrotize PR & Communications
     +45 6062 9390
     tsp@carrotize.com

Attachment

• Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy

SCOTTSDALE, Ariz., Oct. 30, 2026 (GLOBE NEWSWIRE) — Caliber (Nasdaq CWD), a diversified real estate and digital asset management platform, today announced that it will release its third quarter 2026 financial results after the close of the stock market on Thursday, November 12, 2026. Management invites all interested parties to its webcast/conference call the same day at 5:00 pm ET to discuss the results.

Investors and interested parties can access the live earnings call by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) and ask to join the Caliber call or use conference ID 3070057.

To listen to the call online, investors can visit the investor relations page of Caliber’s website at https://ir.caliberco.com/. The webcast replay of the conference call will be available on Caliber’s website shortly after the call concludes.

Additional details:
The news release and presentation materials will also be available on the Investor Relations site under “Financial Results”.

About Caliber (CaliberCos Inc.)
Caliber (Nasdaq: CWD) is a real estate-focused alternative asset manager with over $2.6 billion in Managed Assets and a 17-year track record investing in middle-market hospitality and multifamily real estate. The Company pairs an institutional-quality asset management platform with a boutique, hands-on investment approach focused on value creation in underserved market segments. Investors can participate in Caliber through its publicly traded equity (Nasdaq: CWD), and through its private real estate investment funds for accredited investors and financial professionals. For more information, visit caliberco.com.

Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the Company’s public offering filed with the SEC and other reports filed with the SEC thereafter. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

CONTACTS:
Caliber Investor Relations:
Ilya Grozovsky
+1 480-214-1915
Ilya@CaliberCo.com

Transaction in Own Shares

29 October, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 29 October, 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
29/10/2026	821,526	£41.0800	£39.9400	£40.5003	LSE	GBP
29/10/2026	209,477	£41.0950	£39.9350	£40.5394	Chi-X (CXE)	GBP
29/10/2026	67,997	£41.0900	£39.9450	£40.5697	BATS (BXE)	GBP
29/10/2026	481,906	€49.3200	€47.9400	€48.5187	XAMS	EUR
29/10/2026	205,030	€49.3000	€47.9700	€48.5086	CBOE DXE	EUR
29/10/2026	26,758	€49.2000	€48.0300	€48.5050	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme announced on 29 October 2026.

In respect of this programme, BNP Paribas (with respect to the on-market limb) and Natixis (with respect to the off-market limb) will make trading decisions in relation to the securities independently of the Company for a period from 29 October 2026 up to and including 29 January 2027.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by BNP Paribas and Natixis on behalf of the Company as a part of the buy-back programme is detailed below.  

Enquiries

Media: International +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

LEI number of Shell plc: 21380068P1DRHMJ8KU70

Classification: Acquisition or disposal of the issuer’s own shares

Attachment

• SHELL_RNS_Report_PDF-20261029Cons

Grant protects deliverz.ai’s navigation technology, supporting Gix’s broader Physical AI strategy

TEL AVIV, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) — Gix Internet Ltd. (Nasdaq: GIXI; TASE: GIX) (“Gix” or the “Company”), a dual-listed technology company, today announced that its wholly owned subsidiary, deliverz.ai (“Deliverz”), has been granted a patent in South Korea (Application No. 10-2022-7013675) titled “NAVIGATION INDICATION OF A VEHICLE.” The formal grant follows the previously announced allowance of the application in August 2026.

The patent covers a method and system for providing navigation indications for a vehicle between two points, based in part on visual information from the surrounding environment. The invention describes a method and system for navigating a vehicle from a first location to a second location by using images captured from the vehicle’s surroundings to identify visual cues from a database of visual cues, and to generate accurate location information for the vehicle. The technology is intended to support autonomous vehicle and robot navigation.

The grant strengthens protection for navigation technology that supports Gix’s broader Physical AI strategy: an AI-powered management and orchestration layer coordinating robots, people and autonomous systems. The patent relates to navigation; the broader orchestration platform forms part of the Company’s business strategy.

The South Korean patent grant extends the international protection of this technology alongside patents already granted in Europe and Israel. The patent grant further expands the international protection of Deliverz’s technology and represents a positive development supporting the Company’s growth strategy.

Deliverz’s platform combines management software, autonomous mobile robots and human couriers to coordinate deliveries in real time. It allocates tasks by location, priority and availability from a central operations system, with the aim of improving reliability, throughput and cost efficiency in complex facilities such as hospitals.

“Our strategy is to build an intelligent management layer that coordinates robots, people and autonomous systems in real-world operations. Protecting the navigation technology used by our robots strengthens an important part of that foundation,” said Amir Nardimon, Chief Executive Officer of Gix. “The South Korean patent grant broadens our international IP protection as we continue to develop Deliverz’s commercial use in hospital logistics and pursue opportunities to apply our Physical AI platform in additional complex environments.”

About Gix Internet Ltd.

Gix Internet Ltd. is a technology company that is listed on the Nasdaq Capital Market under the symbol GIXI and on the Tel Aviv Stock Exchange under the symbol GIX. Its operating focus is deliverz.ai, a wholly-owned company that develops an AI-powered management and orchestration layer for robots, people and autonomous systems, commercially proven today in hospital logistics. The platform combines management software with autonomous mobile robots and human couriers to schedule and assign internal deliveries in real time – by location, priority and availability – from a central operations system. It is built for last-mile movement inside complex, high-traffic facilities such as hospitals, is in commercial use at Sheba Medical Center, and is being introduced to U.S. healthcare organizations. Gix’s broader strategy is to extend the same management architecture to additional autonomous systems and complex physical operating environments. Gix also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company. For more information, visit https://www.gix-internet.com/.

About deliverz.ai

deliverz.ai is defining the future of healthcare logistics automation with an end-to-end, AI-powered orchestration platform that unifies autonomous robots, human transport teams, and hospital workflows into a single intelligent system. Robot-agnostic and built to scale, deliverz.ai automates and optimizes logistics across any workflow and within any environment, increasing throughput, reducing costs, and improving both patient and staff experience. Delivered through a flexible Software as a Service (SaaS) and Robotics as a Service (RaaS) model, deliverz.ai provides the intelligent logistics backbone for hospitals, making operations smarter, faster, and patient-centered. For more information, visit https://www.deliverz.ai

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gix’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential contribution of the patent grant and patented technology to the Company’s Physical AI strategy, the potential applications and benefits of its technology, the continued development and commercialization of Deliverz’s technology, and the Company’s plans and objectives regarding the expansion of its Physical AI platform into additional operating environments. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement on Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Gix is not responsible for the content of third-party websites. IBM, IBM Quantum and the names of IBM quantum processors are trademarks of International Business Machines Corporation; IBM is not affiliated with, and has not endorsed, Gix, QXL or the results described in this press release.

Investor Relations Contact:
Michal Efraty
Investor Relations
michal@efraty.com

MONTREAL, Oct. 30, 2026 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) announced today that its Board of Directors has approved a fourth-quarter 2026 dividend on the Company’s common shares outstanding. A quarterly dividend of ninety-one and a half cents (C$0.9150) per common share will be paid on December 30, 2026, to shareholders of record at the close of business on December 9, 2026.

About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

Contacts:
Media	Investment Community
Ashley Michnowski	Jamie Lockwood
Senior Manager	Vice-President, Investor Relations
Media Relations	and Special Projects
(438) 596-4329	(514) 399-0052
media@cn.ca	investor.relations@cn.ca

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio’s cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers:

• Anjali Owens, M.D., Associate Professor of Medicine and Medical Director, Penn Center for Inherited Cardiovascular Disease, Perelman School of Medicine at the University of Pennsylvania
• Mariko Harper, M.D., Medical Director, Hypertrophic Cardiomyopathy Center of Excellence, Virginia Mason Franciscan Health

A live question-and-answer session will follow the formal presentations. 

Interested parties should register for the event at the following link: HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor. A live webcast of the event will be accessible by visiting the Investor Relations section of the Braveheart Bio website at https://ir.braveheart.bio/. A link to the webcast replay will be available in a temporary archive following the event.

About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit www.braveheart.bio.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced two upcoming presentations, including a late-breaking presentation of 52-week extension data for BHB-1893 in obstructive HCM, at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, IL. Following the presentations, copies of the presentation materials will be available in the Investors section of the Braveheart Bio website.

Oral Abstract Presentation

Title: HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in vitro Studies and Patients
Presenter: Carlos del Rio, Ph.D., Senior Vice President, Cardiovascular Research & Translational Science, Braveheart Bio
Date: Friday, November 6, 2026
Session Title: Hypertrophic Cardiomyopathy Medical Society Abstract Oral Presentations
Session Time: 9:45 AM – 10:45 AM CT
Presentation Time: 10:15 AM – 10:25 AM CT
Location: Room S406A, McCormick Place

Late-Breaking Oral Abstract Presentation

Title: Long-Term Efficacy and Safety of BHB/HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the 52-Week Extension Period
Presenter: Xueyi Wu, M.D., Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China​
Date: Friday, November 6, 2026
Session Title: Hypertrophic Cardiomyopathy Medical Society Late Breaking Oral Abstracts
Session Time: 2:15 PM – 3:15 PM CT
Presentation Time: 2:15 PM – 2:25 PM CT
Location: Room S406A, McCormick Place

About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit www.braveheart.bio.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com